Insider Trading activities of Novus Therapeutics, Inc. (NVUS)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Novus Therapeutics, Inc. (NVUS) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Novus Therapeutics, Inc. since year 2005. Table 2 shows the detailed insider transactions of Novus Therapeutics, Inc. since 2005. The reporting company's ticker symbol is NVUS. The reporting company's CIK number is 1404281.
The total value of stock buying since 2005 is $21,175,469.
The total value of stock sales since 2005 is $3,103,372.
The total value of stock option exercises since 2005 is $193,832.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Novus Therapeutics, Inc. (NVUS).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2019-05 1,292,408 $4,006,464 29,451 $57,478 0 $0
2019-04 0 $0 200 $540 0 $0
2018-09 34,485 $164,338 0 $0 0 $0
2017-05 80,080 $799,997 0 $0 0 $0
2016-03 8,000 $45,920 0 $0 0 $0
2016-01 0 $0 0 $0 28,015 $28,015
2015-11 3,000 $33,750 0 $0 0 $0
2015-09 0 $0 20,326 $278,392 13,500 $56,565
2015-07 0 $0 64,602 $917,164 32,564 $46,262
2015-06 0 $0 59,914 $842,196 25,000 $62,990
2015-04 0 $0 6,825 $85,225 0 $0
2015-03 0 $0 49,141 $712,544 0 $0
2014-09 1,075,000 $16,125,000 0 $0 0 $0
2014-06 0 $0 14,777 $209,833 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Novus Therapeutics, Inc. insiders (NVUS)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2019-05-21 Flesher Gregory J. (Chief Executive Officer) Sale 2,937 1.91 5,612
2019-05-21 Turkel Catherine C. (President) Sale 1,914 1.91 3,657
2019-05-21 Kuwahara Jon (See Remarks) Sale 1,058 1.91 2,021
2019-05-20 Flesher Gregory J. (Chief Executive Officer) Sale 11,701 1.96 22,957
2019-05-20 Turkel Catherine C. (President) Sale 7,623 1.96 14,956
2019-05-20 Kuwahara Jon (See Remarks) Sale 4,218 1.96 8,275
2019-05-02 Chimovits Erez Buy 646,204 3.10 2,003,232
2019-05-02 Orbimed Israel Biofund Gp Limited Partnership Buy 646,204 3.10 2,003,232
2019-04-30 Yook Paul Sale 200 2.70 540
2018-09-12 Turkel Catherine C. (President) Buy 16,632 5.02 83,476
2018-09-11 Turkel Catherine C. (President) Buy 17,048 4.56 77,670
2018-09-05 Turkel Catherine C. (President) Buy 805 3.97 3,192
2017-05-10 Flesher Gregory J. (Chief Executive Officer) Buy 58,959 9.99 589,000
2017-05-10 Turkel Catherine C. (Chief Development Officer) Buy 11,111 9.99 110,998
2017-05-10 Ocampo Christine (See Remarks) Buy 10,010 9.99 99,999
2016-03-15 Buckley Stephen Jr. Buy 8,000 5.74 45,920
2016-01-08 Morrison Jodie Pope (President and CEO) Option Ex 28,015 1.00 28,015
2015-11-11 Buckley Stephen Jr. Buy 3,000 11.25 33,750
2015-09-21 Mcbride John S. (Chief Operating Officer) Sale 13,500 14.01 189,135
2015-09-21 Mcbride John S. (Chief Operating Officer) Option Ex 13,500 4.19 56,565
2015-09-08 Kalowski Lee (Chief Financial Officer) Sale 4,668 13.13 61,290
2015-09-02 Kalowski Lee (Chief Financial Officer) Sale 2,158 12.96 27,967
2015-07-29 Morrison Jodie Pope (President and CEO) Sale 564 13.70 7,726
2015-07-29 Morrison Jodie Pope (President and CEO) Option Ex 10,564 1.19 12,602
2015-07-28 Morrison Jodie Pope (President and CEO) Sale 12,000 13.70 164,400
2015-07-28 Morrison Jodie Pope (President and CEO) Option Ex 12,000 1.58 18,960
2015-07-22 Morrison Jodie Pope (President and CEO) Option Ex 10,000 1.47 14,700
2015-07-15 Novartis Ag (10% Owner) Sale 3,566 14.26 50,844
2015-07-14 Novartis Ag (10% Owner) Sale 27,861 14.41 401,477
2015-07-13 Novartis Ag (10% Owner) Sale 20,611 14.20 292,717
2015-06-29 Morrison Jodie Pope (President and CEO) Sale 8,000 13.70 109,600
2015-06-29 Morrison Jodie Pope (President and CEO) Option Ex 8,000 1.58 12,640
2015-06-26 Morrison Jodie Pope (President and CEO) Sale 8,000 13.83 110,640
2015-06-26 Morrison Jodie Pope (President and CEO) Option Ex 8,000 1.58 12,640
2015-06-24 Mcbride John S. (Chief Operating Officer) Sale 300 14.20 4,260
2015-06-24 Mcbride John S. (Chief Operating Officer) Option Ex 300 4.19 1,257
2015-06-23 Mcbride John S. (Chief Operating Officer) Sale 6,700 14.00 93,800
2015-06-23 Mcbride John S. (Chief Operating Officer) Option Ex 6,700 4.19 28,073
2015-06-22 Mcbride John S. (Chief Operating Officer) Sale 2,000 14.02 28,040
2015-06-22 Mcbride John S. (Chief Operating Officer) Option Ex 2,000 4.19 8,380
2015-06-16 Novartis Ag (10% Owner) Sale 1,120 14.27 15,982
2015-06-12 Novartis Ag (10% Owner) Sale 5,919 14.20 84,049
2015-06-11 Novartis Ag (10% Owner) Sale 27,875 14.20 395,825
2015-04-16 Kalowski Lee (Chief Financial Officer) Sale 4,567 13.00 59,371
2015-04-02 Kalowski Lee (Chief Financial Officer) Sale 2,258 11.45 25,854
2015-03-19 Novartis Ag (10% Owner) Sale 46,141 14.50 669,044
2015-03-18 Novartis Ag (10% Owner) Sale 3,000 14.50 43,500
2014-09-22 Apple Tree Partners Ii - Annex, L.p. (Director) Buy 237,500 15.00 3,562,500
2014-09-22 Harrison Seth Loring (Director) Buy 362,500 15.00 5,437,500
2014-09-22 Satter Muneer A (10% Owner) Buy 150,000 15.00 2,250,000
2014-09-22 Novartis Ag (10% Owner) Buy 325,000 15.00 4,875,000
2014-06-15 Novartis Ag (10% Owner) Sale 14,777 14.20 209,833

Insider trading activities including stock purchases, stock sales, and option exercises of NVUS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Novus Therapeutics, Inc. (symbol NVUS, CIK number 1404281) see the Securities and Exchange Commission (SEC) website.